- Home
- PODC vs QNCX Comparison
PODC vs QNCX Comparison
Compare PODC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- QNCX
- Stock Information
- Founded
- PODC 2013
- QNCX 2012
- Country
- PODC United States
- QNCX United States
- Employees
- PODC N/A
- QNCX N/A
- Industry
- PODC
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PODC
- QNCX Health Care
- Exchange
- PODC Nasdaq
- QNCX Nasdaq
- Market Cap
- PODC 44.1M
- QNCX 43.2M
- IPO Year
- PODC N/A
- QNCX 2019
- Fundamental
- Price
- PODC $1.98
- QNCX $1.06
- Analyst Decision
- PODC Strong Buy
- QNCX Strong Buy
- Analyst Count
- PODC 1
- QNCX 5
- Target Price
- PODC $5.00
- QNCX $8.00
- AVG Volume (30 Days)
- PODC 12.2K
- QNCX 611.7K
- Earning Date
- PODC 06-10-2025
- QNCX 05-13-2025
- Dividend Yield
- PODC N/A
- QNCX N/A
- EPS Growth
- PODC N/A
- QNCX N/A
- EPS
- PODC N/A
- QNCX N/A
- Revenue
- PODC $49,729,000.00
- QNCX N/A
- Revenue This Year
- PODC $20.67
- QNCX N/A
- Revenue Next Year
- PODC $19.09
- QNCX N/A
- P/E Ratio
- PODC N/A
- QNCX N/A
- Revenue Growth
- PODC 22.98
- QNCX N/A
- 52 Week Low
- PODC $1.10
- QNCX $0.51
- 52 Week High
- PODC $2.85
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- PODC 51.42
- QNCX 51.30
- Support Level
- PODC $1.87
- QNCX $1.01
- Resistance Level
- PODC $2.12
- QNCX $1.06
- Average True Range (ATR)
- PODC 0.16
- QNCX 0.11
- MACD
- PODC -0.01
- QNCX 0.02
- Stochastic Oscillator
- PODC 50.75
- QNCX 80.95
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.